Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal strong revenue growth, a strategic sales force expansion, and a promising drug pipeline. Despite minor setbacks in pharmacy capacity impacting financial results, the company's stock repurchase program and optimistic future revenue expectations, particularly for relacorilant, are positive indicators. The Q&A also highlighted management's proactive measures to address pharmacy issues and expand market reach. With a market cap of $3.3 billion, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue $194.4 million in Q2 2025, compared to $163.8 million in Q2 2024, representing a year-over-year increase. The increase is attributed to a surge in demand, with a record number of new prescribers, new prescriptions, and patients on therapy. However, the financial results were slightly impacted by insufficient capacity of the pharmacy vendor.
Net Income $35.1 million in Q2 2025, compared to $35.5 million in Q2 2024, showing a slight year-over-year decrease. The reasons for this decrease were not explicitly mentioned.
Cash and Investments $515 million as of June 30, 2025. This reflects the acquisition of $115 million of common stock under the stock repurchase program, net exercise of stock options by employees, and net vesting of restricted stock grants.
Tablet Shipments 49% increase in the number of tablets shipped in Q2 2025 compared to Q2 2024. This increase is due to a record number of new prescribers and patients on therapy.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Relacorilant: Expected approval for hypercortisolism by December 30, 2025. Positioned as a new standard of care due to strong efficacy and safety. Anticipated to generate $3 billion to $5 billion in annual revenue in hypercortisolism alone within 3-5 years.
Relacorilant in Oncology: Submitted NDA for platinum-resistant ovarian cancer. Demonstrated significant improvement in progression-free survival and overall survival in the ROSELLA trial. Positioned to become a new standard of care for this condition.
Miricorilant: Phase IIb MONARCH study for NASH nearing completion. Early results show potential in reducing liver fat and improving liver health markers.
Dazucorilant: Phase II trial in ALS showed potential in reducing early death risk by 84%. Further regulatory engagement ongoing.
Hypercortisolism Market: CATALYST trial results indicate a far higher prevalence of hypercortisolism than previously assumed. Increased physician awareness and screening expected to expand the market significantly.
Oncology Market: Relacorilant's success in the ROSELLA trial positions it for broader use in earlier stages of ovarian cancer and other solid tumors.
Pharmacy Capacity Expansion: Increased pharmacy capacity to meet growing demand for hypercortisolism treatments. A second pharmacy is being brought online, with financial impact expected in Q4 2025.
Sales Force Expansion: Increased endocrinology sales team from 60 to 145 clinical specialists, with plans to reach 175 by year-end 2025.
Litigation with Teva: Awaiting Federal Circuit Court decision on patent infringement case. A favorable ruling could block Teva's generic product until 2037.
Cortisol Modulation Platform: Expanding research into cortisol modulation for various diseases, including oncology, neurology, and liver disorders.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Pharmacy vendor capacity: The insufficient capacity of the pharmacy vendor has not kept pace with the company's growth, leading to a delay in fully realizing financial results from increased demand. Although capacity is expected to improve in the second half of the year, this remains a bottleneck for growth.
Patent litigation with Teva: The ongoing patent litigation with Teva poses a risk to the company's ability to protect its intellectual property. If the Federal Circuit Court of Appeals rules against Corcept, Teva may gain FDA approval for a generic version of Korlym, potentially impacting revenue until the patent expiration in 2037.
Regulatory approval timelines: The company is awaiting regulatory approvals for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Delays or unfavorable decisions could impact the company's ability to bring these products to market and achieve projected growth.
Competition in hypercortisolism treatment: The company faces competitive pressures in the hypercortisolism treatment market, particularly from existing medications like Ozempic and Mounjaro. While relacorilant is expected to be a superior option, its success depends on physician adoption and market penetration.
Oncology market challenges: While relacorilant has shown promise in oncology, its success in becoming a standard of care for platinum-resistant ovarian cancer depends on physician adoption and competition from other treatments. Additionally, the company is entering a highly competitive oncology market.
ALS trial results: The DAZALS trial for ALS did not meet its primary endpoint, raising questions about the viability of dazucorilant as a treatment option. While there were promising findings related to early death prevention, the overall results may impact the drug's future development and market potential.
Supply chain and operational scalability: The company is rapidly expanding its sales force and operational capacity to meet growing demand. However, scaling operations effectively to match growth remains a challenge and could impact performance if not managed well.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has modified its 2025 revenue guidance to $850 million to $900 million.
Pharmacy Capacity Expansion: Pharmacy capacity will increase further in the second half of the year, with financial impact expected in the fourth quarter. A second pharmacy is being brought online.
Relacorilant Approval and Revenue Projections: Relacorilant is anticipated to be approved by December 30, 2025, and is expected to generate $3 billion to $5 billion in annual revenue in hypercortisolism alone within the next 3 to 5 years.
Oncology Division and Relacorilant in Cancer: Relacorilant's NDA for platinum-resistant ovarian cancer has been submitted, with approval expected next year. The company is preparing to bring relacorilant plus nab-paclitaxel to market upon approval.
Pipeline Developments: The company is advancing studies in prostate cancer, immunotherapy combinations, and other tumor types. It is also exploring dazucorilant for ALS and miricorilant for liver diseases, with results from the MONARCH study expected late next year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: Our cash and investments at June 30 were $515 million. Balance reflects our acquisition of $115 million of our common stock in the second quarter, pursuant to our stock repurchase program, the net exercise of stock options by Corcept employees and the net vesting of restricted stock grants.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What portion of the business came from the authorized generic (AG) during the quarter relative to Q1, and what is the pricing headwind in percentage terms year-over-year?
A:Over 50% of the business had transitioned to the AG in Q1, and this increased to about 2/3 in Q2. The AG was launched at a 12% discount to Korlym's list price, but on average, payers negotiate to about a 30% discount.
Q:What is the disconnect between prescriptions written and filled, and did the gap narrow in Q2 compared to Q1?
A:The pharmacy did not meet expectations, though there was improvement in Q2. The gap narrowed but not completely, with a $15 million impact on Q2 results. A second pharmacy is being onboarded to address this issue, expected to contribute in Q4.
Q:Regarding the $3 billion to $5 billion peak sales opportunity for the hypercortisolism franchise, how much is coming from Korlym, and how important is winning the ongoing appeals process with Teva?
A:Relacorilant is expected to entirely replace Korlym due to its advantages. The $3 billion to $5 billion estimate includes relacorilant and assumes a small market penetration. Winning the patent case with Teva does not impact this estimate as it pertains to Korlym.
Q:When will the second pharmacy come online, and will more distributors be activated for relacorilant?
A:The second pharmacy is expected to contribute in Q4. The network will expand further if needed, especially for relacorilant.
Q:Why was a second pharmacy not onboarded earlier, and why is guidance being pulled down despite the second pharmacy coming online in Q4?
A:The rapid growth from CATALYST data was unexpected, and the original pharmacy was thought to be sufficient. Guidance was lowered due to delays in patient medication access, which have a cumulative impact beyond the $15 million Q2 effect.
Q:What is the timeline for the BELLA study, and are there plans to evaluate relacorilant in other solid tumors?
A:BELLA will complete enrollment by the end of the year, with results expected a year later. Relacorilant will be studied in ovarian cancer, endometrial cancer, cervical cancer, and other solid tumors, including prostate cancer.
Q:What is the strategy for FDA discussions on ALS, and will another study be conducted?
A:A meeting with the FDA is scheduled for August. Options include approval based on current data or conducting a confirmatory trial, which is expected regardless of the FDA's decision.
Q:What is the positioning of BELLA in the treatment paradigm for ovarian cancer, and will it be used in earlier stages?
A:BELLA supports flexible use in multiple lines of therapy, including earlier stages of platinum-resistant ovarian cancer. Its safety profile and ease of use make it appealing for earlier utilization.
Q:Are there concerns about overlapping toxicities when using relacorilant in combination with other therapies like immunotherapy or ADCs?
A:There are no concerns about overlapping toxicities. Relacorilant is expected to synergize with other therapies without added toxicity.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing why a second pharmacy was not onboarded earlier, providing a hindsight explanation without specific details. Additionally, the response to the ALS FDA strategy was vague, emphasizing possibilities without concrete plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Appeals briefing
Balance acquisition
Belanoff Co
Canaccord Genuity
Capacity record
Care field
Chief Judge
Circuit Dr
Circuit decision
Co LLC
Co Research
Conference CFO
Corp Research
Court decision
Director Roberto
District Court
Division Joon
Division PM
Division Swayampakula
Division Xinwei
Dr Belanoff
ET Corcept
Genuity Corp
Judge decision
Research Division
capacity
law
opinion
panel
pharmacy
place
record number
stock
tablet
validity patent
CORT Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call presents mixed signals. Financial performance shows revenue growth but a significant net loss. Product updates are promising, with positive trial results and optimistic guidance for Cushing's syndrome and oncology drugs. However, operational challenges, regulatory risks, and competitive pressures persist. The Q&A reveals confidence in relacorilant and Lifyorli but highlights market competition and supply chain issues. No share buyback or dividend program is mentioned. Considering the market cap and mixed outlook, the stock price is likely to remain stable, with a neutral sentiment over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript
Positive2-24
The company's earnings call highlights strong revenue growth, a successful stock repurchase program, and strategic pharmacy transitions to meet demand. Despite a decline in net income, the optimistic guidance and potential FDA approvals for relacorilant support a positive outlook. The Q&A section reveals confidence in resolving supply chain issues and potential new oncology standards. However, uncertainties with the FDA and price erosion concerns slightly temper the sentiment. Given the market cap, the stock is likely to react positively, with a predicted movement of 2% to 8% over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed picture: revenue growth and strategic expansion in pharmacy capacity are positive, but the significant drop in net income and lack of priority review for the ovarian cancer NDA are concerns. The Q&A reveals confidence in handling increased volume and no downward pressure on margins, but management's vague responses on certain issues may worry investors. The market cap is moderate, suggesting a neutral stock price movement, balancing positive growth prospects with current financial challenges.
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Positive8-1
The earnings call summary and Q&A reveal strong revenue growth, a strategic sales force expansion, and a promising drug pipeline. Despite minor setbacks in pharmacy capacity impacting financial results, the company's stock repurchase program and optimistic future revenue expectations, particularly for relacorilant, are positive indicators. The Q&A also highlighted management's proactive measures to address pharmacy issues and expand market reach. With a market cap of $3.3 billion, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
CORT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
